Benzinga's Small Cap Movers for Tuesday December 18, 2012
Below are highlights from Benzinga's daily coverage of small cap securities making big moves:
Better Online Solutions
Shares of Better Online Solutions (NASDAQ: BOSC), the Israel-based provider of RFID and Supply Chain solutions to global enterprises, rose almost 8% Tuesday on 2.5 times average volume.
Better Online Solutions announced Friday that the reverse share split previously announced by the Company on October 31, 2012, shall become effective on December 14, 2012. Pursuant to the reverse split, each 4 Ordinary Shares, NIS 20.00 nominal value per share, will be converted into one Ordinary Share, NIS 80.00 nominal value per share. No fractional shares will be issued as a result of the reverse-split. Instead, all fractional shares will be rounded up to the next higher whole number of shares.
Better Online Solutions closed at $4.72 on Tuesday.
Shares of PokerTek (NASDAQ: PTEK), the Matthews, NC licensed gaming company that develops and markets electronic table game solutions for the gaming industry, rose 45% Tuesday on 4 times average volume.
PokerTek announced Tuesday that it has re-entered the Mexico gaming market. Installations of PokerPro have commenced with games in several locations already live and in play.
"We are excited to see PokerPro back on the floor in Mexico, a market which previously represented over 17% of annualized recurring revenue," commented Mark Roberson, Chief Executive Officer. "Installations in Mexico will begin contributing incremental recurring revenue immediately, with 14 tables representing 140 gaming positions already in place and additional sites in planning for the rest of December and early 2013. Our re-entry into the Mexico market represents a significant catalyst for revenue growth and EPS profitability."
PokerTek closed at $1.05 on Tuesday.
Shares of Vanda Pharmaceuticals (NASDAQ: VNDA), the Washington, DC biopharmaceutical company, rose 19% Tuesday on 19 times average volume.
Vanda Pharmaceuticals announced Tuesday positive results from the SET Phase III study, evaluating tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder (Non-24). Tasimelteon succeeded in the primary endpoint of Entrainment of the melatonin (aMT6s) rhythm as compared to placebo.
Vanda Pharmaceuticals closed at $3.83 on Tuesday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.